荷丹片联合阿托伐他汀治疗冠心病的临床研究

Clinical Efficacy of Hedan Tablet Combined with Atorvastatin in Treatment of Coronary Heart Disease

目的:观察荷丹片联合阿托伐他汀治疗冠心病的临床治疗效果以其为临床诊疗提供参考。方法:分析2015年1月—2016年1月在我院接受诊疗的冠心病(稳定性心绞痛)患者的资料。依据治疗药物的不同将患者分为观察组(阿托伐他汀+荷丹片)及对照组(阿托伐他汀)。对比两组患者治疗期12个月内心绞痛的累积发生率并检测相关血液学指标的改变。结果:本研究共纳入观察组41例,对照组44例。观察组治疗期间心绞痛的累积发生率显著低于对照组(14.63%,6/41 vs 36.36%,16/44;Log-rankχ~2=5.619,P=0.018)。治疗后,观察组与对照组TC、TG、LDL-c水平均显著降低(P<0.05),但观察组低于对照组患者(P<0.05)。治疗后,两组患者治疗后HDL-c水平均显著升高(P<0.05),但观察组高于对照组患者(P<0.05)。治疗后,观察组与对照组CRP、MMP-1、PAPP-A水平均显著降低(P<0.05),但观察组低于对照组患者(P<0.05)。结论:联合使用荷丹片可显著降低冠心病患者心绞痛发作频率,可能与其调控血脂、抗炎及提高动脉粥样斑块稳定等疗效有关。

Objective：Our study was aimed to analyze the clinical efficacy of Hedan Tablet combined with atorvastatin in the treatment of coronary heart disease. Methods ： Clinical data of patients with coronary heart disease received treatment at our hospital from 2015 to 2016 was analyzed. Patients were divided into two groups by therapeutic methods. Group A：Hedan Tablet ＋ atorvas- tatin ; Group B ： atorvastatin. Results ： A total of 85 patients were analyzed, Group A 41 cases, Group B 44 cases. During 12 months treatment, Group A patients had lower accumulate incidence of stenocardia than that of Group B and the difference was statistically significant （ 14.63 % ,6/41 vs 36.36%, 16/44 ; Log - rank X^2 = 5.619, P = 0.018 ）. After treatment, both of the two groups got significant decrease in TC, TG, LDL - c （ P 〈 0. 05 ） and increase in HDL - c （ P 〈 0. 05 ）, but the changes of these indexes were more remarkably in Group A （P 〈 0. 05 ）. Both of the two groups got significant decrease in CRP, MMP - 1 PAPP - A （ P 〈 0. 0）, but these markers were lower in Group A when compared with Group B （P 〈 0. 0）. Conclusion：In the treatment of coronary heart disease, Hedan Tablet can significantly improve the clinical efficacy, which may be associated with its functions of anti - inflammatory, reducing blood lipids and stabilized the atherosclerotic plaque.